Back to Search
Start Over
Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström macroglobulinemia
- Source :
- Blood Advances; 20240101, Issue: Preprints
- Publication Year :
- 2024
-
Abstract
- •Patients with Waldenström macroglobulinemia and mutations in CXCR4or TP53had poorer prognosis after treatment with BTK inhibitors.•Patients with CXCR4or TP53mutations had more favorable outcomes when treated with zanubrutinib versus ibrutinib.
Details
- Language :
- English
- ISSN :
- 24739529 and 24739537
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Blood Advances
- Publication Type :
- Periodical
- Accession number :
- ejs65434427
- Full Text :
- https://doi.org/10.1182/bloodadvances.2023010906